| Name | Title | Contact Details |
|---|---|---|
Christopher Slee |
Chief Technology Officer | Profile |
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
American Postal Workers Union Health Plan is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discover Research Inc is a Beaumont, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Behavioral Dimensions Inc is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chesapeake IRB and its Canadian affiliate, IRB Services, have been in business since 1993. They have established a reputation for excellence that is based on quality work, efficient processes, and excellent customer service. Chesapeake IRB`s schedule of 5 weekly meetings, daily expedited review capability, 4 day turnaround for protocols and 24-hour turnaround for Principal Investigators (PIs) has helped our clients become more competitive for industry sponsored studies; including Phase I research. While the majority of our studies are biomedical or device related, we have a broad range of social/behavioral studies that are often government or foundation funded. We work with you as a risk mitigation partner to meet your needs.